Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Belantamab Mafodotin After BCMA CAR-T in RRMM
NCT05117008Phase 2Terminated
- Sponsor
- Medical College of Wisconsin
- Start
- Jul 2022
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of belantamab mafodotin in multiple myeloma (MM), sponsored by Medical College of Wisconsin. Started Jul 2022; status: terminated.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05117008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05117008.